Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: The effect on survival

Menopause

Volumn 8, Issue 1, 2001, Pages 70-75

  Uršič Vršaj, Marjetka ^a   Bebar, Sonja ^a   Žakelj, Maja Primic ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Hormone replacement therapy; Invasive ovarian serous cystadenocarcinoma; Ovarian cancer; Survival

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; NORETHISTERONE ACETATE; PRASTERONE; PROGESTERONE;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTADENOCARCINOMA; DIAGNOSTIC ACCURACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; OVARY CANCER; PATIENT SELECTION; REGRESSION ANALYSIS; RELIABILITY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

EID: 0035148594     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200101000-00012     Document Type: Article

References (13)

1. Are there any arguments against hormone replacement therapy after treatment of ovarian adenocarcinoma?
2. Hormone replacement therapy in women with a prior diagnosis of ovarian cancer
3. Estrogen replacement therapy and risk of epithelial ovarian cancer
4. Contemporary therapy of the menopausal syndrome
5. High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group
6. Molecular genetics of hereditary ovarian cancer
7. Hormone replacement therapy and cancer
8. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis
9. Controversial issues in the management of early epithelial ovarian cancer: Conservative surgery and role of adjuvant therapy
10. Hormone replacement therapy and survival after surgery for ovarian cancer
11. Hormone replacement therapy and ovarian cancer